Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Carpenter Technology Corporation promoted Marshall D. Akins to Senior Vice President – Chief Operating Officer, effective immediately. The company also announced the promotions of John Huyette to Vice President – Chief Commercial Officer and Bill Besash to Vice President – Investor Relations and Corporate Development. Mr. Akins will receive a base salary of $580,000 and an annual equity incentive award valued at $1.3 million.
Luvu Brands reported first quarter fiscal 2027 net sales growth of 10% to $6.8 million, driven by strength in wholesale and international channels. Despite the revenue growth, the company reported a net loss of $365,000 as higher freight and manufacturing labor costs compressed gross margins to 26.2%.
Term
Q1 2027
“We opened fiscal 2027 with double-digit top-line growth, led by continued strength in our Wholesale channel, particularly adult retailers and international customers, and by better conversion on our Liberator website following its move to the Shopify platform. We are adding distribution points at home and abroad, and we are encouraged by the momentum in both our Direct and Wholesale channels.”
Louis Friedman, Founder, Chief Executive Officer of Luvu Brands
Roadzen reported record quarterly revenue of $17.6 million for Q2 fiscal 2027, representing 28.6% year-over-year growth. The company achieved its first-ever positive Adjusted EBITDA quarter and narrowed its operating loss by 24% as it targets a $100 million annualized revenue run rate by fiscal year-end.
Term
Q2 2027
“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”
Rohan Malhotra, Founder and CEO of Roadzen
“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”
Roadzen reported record revenue of $17.6 million for the second fiscal quarter, up 28.6% year-over-year, and achieved its first positive Adjusted EBITDA quarter in company history. The company also announced a $10 million equity financing for its India subsidiary at a $300 million post-money valuation and reaffirmed its target to exit fiscal 2027 at a $100 million-plus annualized revenue run rate.
Term
Q2 2027
“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”
Rohan Malhotra, Founder and CEO of Roadzen
“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”
Infleqtion reported record Q3 2026 revenue of $9.1 million, a 25% year-over-year increase, driven by its neutral atom quantum computing and sensing business. The company achieved a major technical milestone by demonstrating 30 logical qubits and maintained its full-year 2026 revenue guidance of at least $45.1 million.
Term
Q3 2026
“We are building Infleqtion to lead in utility-scale quantum computing, and this quarter’s progress strengthens our confidence in that ambition. Delivering 30 logical qubits is an important step on our technology roadmap. Alongside that progress, growth in our backlog and remaining performance obligations gives us confidence in a strong 2027 across computing and sensing, with computing becoming a meaningfully larger part of our business.”
agilon health, inc. is hosting a virtual investor event on November 17, 2026, to present its strategic framework for driving performance at scale. The company filed a formal investor presentation deck as an exhibit, which includes discussions on its technology-enabled clinical programs and long-term growth trajectory.
AECOM reported fourth quarter and full year fiscal 2026 results, achieving record wins and a 13% backlog growth to an all-time high of $28.0 billion. The company also announced a 10% increase in its quarterly cash dividend to $0.34 per share and initiated fiscal 2027 guidance reflecting strong growth expectations.
Term
FY2026
“Our full year performance, including record wins, backlog and fourth quarter margins, strengthen our confidence that our strategy and investments are delivering results.”
Troy Rudd, AECOM’s chairman and chief executive officer
“Our underlying cash flow was very strong, resulting in full year free cash flow that was ahead of our prior guidance.”
Gaurav Kapoor, AECOM’s chief financial and operations officer
Stem, Inc. reported Q3 2026 financial results, highlighting a shift in strategy to focus on its high-margin PowerTrack software while de-emphasizing Managed Services and battery hardware resale. The company achieved record solar assets under management of 40 GW and reported positive adjusted EBITDA of $7.1 million, though it lowered full-year revenue and ARR guidance due to the strategic pivot.
Term
Q3 2026
“Our third quarter shows the operating leverage of a business built around PowerTrack. PowerTrack software revenue grew 18% year-over-year, we achieved a record 40 gigawatts of solar assets under management, and we were selected for the first utility-scale solar project in the Republic of Georgia.”
Arun Narayanan, Chief Executive Officer of Stem
“We delivered another quarter of strong margins and adjusted EBITDA, with non-GAAP gross margin of 58% and adjusted EBITDA of $7.1 million, more than triple the third quarter of 2025.”
Valion Bio held a special meeting of stockholders on November 12, 2026, where shareholders approved three key proposals. These included granting the board discretionary authority to effect a reverse stock split (ratio between 1-for-2 and 1-for-12) and amending the 2021 Equity Incentive Plan to increase the authorized share reserve by 272,000 shares.
Richardson Electronics COO Wendy Diddell Sells $140K of Stock
Wendy Diddell, COO, sold 6,993 shares of Richardson Electronics, Ltd. at $20.03 a share, worth $140K in total on Nov 12, 2026. Shares held after the trade: 107,157 (-6.1%).
Amdocs Director Adrian Gardner Buys $215K of Stock
Adrian Gardner, Director, bought 5,000 shares of Amdocs Ltd at $43.02 a share, worth $215K in total on Nov 12, 2026. Shares held after the trade: 25,000 (+25.0%).
Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.
Counterparty
Nasdaq
Term
180 days
“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
CervoMed presented 24-week interim biomarker data from its Phase 2a trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed an exposure-dependent reduction in neurofilament light chain (NfL), a key biomarker of neuronal damage, in patients with higher plasma drug levels. Full 24-week biomarker and clinical data from the study are expected in the first quarter of 2027.
Rapid Micro Biosystems M&A Deal with Merck KGaA, Darmstadt, Germany
Rapid Micro Biosystems has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany for $0.75 per share in an all-cash tender offer. Following the transaction, which is expected to close in December 2026, Rapid Micro Biosystems will become a wholly owned subsidiary of Merck KGaA's Life Science business. The deal aims to expand the reach of the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing.
BrainStorm Cell Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update on its Phase 3b ENDURANCE study of NurOwn in ALS. The company highlighted the appointment of former FDA official Professor Peter J. Pitts as Executive Chairman to lead regulatory and capital-markets initiatives. Net loss for the quarter was $2.1 million, or $0.03 per share, as the company prepares for the initiation of its next clinical trial phase.
Term
Q3 2026
“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options. We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment.”
Chaim Lebovits, President and Chief Executive Officer
Aqua Metals reported third quarter 2026 financial results, highlighting a 19% year-over-year reduction in operating expenses. The company established offtake pathways via letters of intent for all three primary product streams at its Project Headwaters ARC facility, including copper, aluminum, and lithium carbonate.
“The third quarter was about converting commercial discussions into agreements and lowering the cost of carrying the business while we advance the funding strategy for Project Headwaters ARC.”
Steve Cotton, President and Chief Executive Officer
“We end the quarter with offtake pathways across all three primary product streams, a better-defined Phase 1 project and a lower cost base. Each of those puts Aqua Metals in a better position to act as funding and policy conditions become clearer.”
Steve Cotton, President and Chief Executive Officer
Mid-America Apartment Communities (MAA) filed a formal investor presentation deck to be used at the Nareit REITworld conference from November 17-19, 2026. The presentation provides strategic highlights and operational updates for the multifamily REIT. The filing was made under Item 7.01 of Form 8-K to comply with Regulation FD.
Guardant Health $550M Debt Financing with U.S. Bank Trust Company, National Association
Guardant Health completed a private offering of $550 million in 0% Convertible Senior Notes due 2032, which included the full exercise of the initial purchasers' option for an additional $50 million. The notes feature an initial conversion price of approximately $208.95 per share, representing a 35% premium over the November 11, 2026 closing price. Proceeds will be used to repurchase a portion of the company's existing 2027 convertible notes, fund capped call transactions, and for general corporate purposes.
MetLife, Inc. declared quarterly cash dividends on its Series A, Series E, and Series F non-cumulative preferred stock. The dividends are payable on December 15, 2026, to shareholders of record as of November 30, 2026.
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.
InPoint Commercial Real Estate Income Business Update
InPoint Commercial Real Estate Income, Inc. announced its monthly Net Asset Value (NAV) per share as of October 31, 2026. The aggregate NAV per share was determined to be $13.4472, with total net asset value attributable to common stock of approximately $136.1 million.
FB Financial Corporation made available an investor presentation for use by management during various conferences in the fourth quarter of 2026. The presentation provides a strategic overview of the company's business segments, including its banking and mortgage operations.
Western Digital $1.5B Debt Financing with Bank of America, N.A.
Western Digital entered into a new $1.5 billion senior unsecured revolving credit facility maturing in 2031, replacing its existing 2022 loan agreement. The new facility features a $200 million sublimit for letters of credit and interest rates based on the company's credit ratings. The agreement includes a maximum leverage ratio covenant of 3.25 to 1.00, which can be temporarily increased following material acquisitions.
Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The FDA has granted a rolling submission for the application, which will use data from the FIGHT DMD trial compared against natural history databases. The decision to file follows several regulatory meetings where the company addressed FDA questions regarding Phase 2 study results and efficacy endpoints.
AEON Biopharma reported Q3 2026 financial results and provided a regulatory update on its ABP-450 biosimilar program. The company received FDA Type 2b feedback clarifying its development strategy and submitted an IND for a comparative pharmacodynamic study planned for Q1 2027.
Term
Q3 2026
“Over the past several months, we have made important progress in advancing the scientific and regulatory foundation for ABP-450’s development as a biosimilar to BOTOX®.”
Rob Bancroft, President and Chief Executive Officer
“With our CMAP IND submitted and additional capital secured through the recent milestone warrant exercises, we are positioned to advance the next phase of development, including the planned initiation of our comparative pharmacodynamic study in the first quarter of 2027.”
Rob Bancroft, President and Chief Executive Officer
Stem, Inc. announced that Saul Laureles, Chief Legal Officer and Secretary, will leave the company effective November 24, 2026. The Board has appointed Jessica Palomino, the company's current Vice President and Senior Counsel – Operations, to succeed him as Chief Legal Officer and Secretary on the same date. Mr. Laureles will remain as a non-executive advisor through December 13, 2026, to ensure an orderly transition.
Dave Inc. has filed applications with the OCC and FDIC to establish Dave Bank, N.A. as a full-service national bank and wholly-owned subsidiary. The company also intends to apply to the Federal Reserve to become a bank holding company, a move intended to allow Dave to offer deposit and credit products directly under federal supervision. In connection with the application, Anthony Sharett has been appointed as Chief Banking Officer and proposed President of the Bank.
Jacobs Solutions Inc. has appointed Richard D. Phillips to its Board of Directors, effective December 1, 2026, increasing the board size to 10 members. Phillips, currently the CEO of Kimball Electronics and a former McKinsey partner, will receive a $135,000 annual cash retainer and a pro-rated $200,000 annual RSU award. The appointment adds significant public company leadership and strategic advisory experience to the board as the company executes its long-term strategy.
Sun Communities, Inc. filed a formal investor presentation deck (Exhibit 99.1) to be used for investor meetings beginning November 16, 2026. The presentation provides strategic highlights and operational updates following the company's completed sale of its Park Holidays business unit.
Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.
Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.
Value
$56M
Counterparty
Rosemont Pharmaceuticals Holdings, Inc.
“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”
Josh Disbrow, Chief Executive Officer of Aytu
“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”